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Objectives: To estimate human immunodeficiency virus (HIV) incidence using HIV
avidity assays in Korea, we established a serological testing method to differ-
entiate recent HIV infections from long-standing ones.
Methods: We adopted two incidence assays, the BED HIV-1 incidence test
(Calypte Biomedical) and an HIV avidity assay (using Abbott AxSYM HIV Antigen/
Antibody Combo), and performed them on Korean HIV samples obtained from 81
HIV seroconverters (n Z 193), 135 HIV-positive samples, and three HIV com-
mercial incidence panels (PRB965, PRB933, and PRB601 from SeaCare). To
determine the most optimal concentration of the chaotropic agent (Guanidine)
and the cutoff value for the avidity assay, we evaluated the sensitivity and
specificity of the assay at different concentration levels.
Results: We determined that the concentration of Guanidine to be used in the
avidity assay was 1.5M. The cutoff value of the avidity index (AI) was 0.8, and the
sensitivity and specificity were 90.2% and 83.8%, respectively, under this condi-
tion. The gray zone for the avidity assay was 0.75e0.85 AI. The mean of coef-
ficient of variation was low, at 5.43%.
Conclusion: An optimized avidity assay for the diagnosis of recent HIV infections
using Korean samples was established. This assay will be applied to investigate
the level of recent infection and will provide basic data to the HIV prevention
policy in Korea.@korea.kr (S.S. Kim).
ted under the terms of the Creative Commons Attribution Non-Commercial License (http://
) which permits unrestricted non-commercial use, distribution, and reproduction in any
operly cited.
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HIV avidity assay to identify recent HIV infections 1851. Introduction
Recently, the focus of epidemiological studies on
human immunodeficiency virus (HIV) has shifted from
the surveillance of prevalence to the measurement of
incidence [1]. As a barometer to monitor the current
level and changes in infection, HIV incidence can pro-
vide a scientific rationale for new policy development as
well as for immediate and direct evaluation of preven-
tive programs.
In the case of HIV, antibody levels peak within 6
months after infection because of a rapid immunological
response. As a result, it is difficult to distinguish recent
infections using standard commercial screening and
confirmatory tests [2]. Previous studies and clinical
practice often relied on the analysis of the anti-
geneantibody response after infection for diagnosis, and
assessed the progression of infection by measuring
changes in antibody levels [3,4]. Furthermore, consid-
erable effort has been made to develop assays that can
discriminate between recent and long-term HIV in-
fections from a single sampling [5].
The avidity assay is a type of modified enzyme-
linked immunosorbent assay (ELISA), in which a sam-
ple is treated with a chaotropic agent (e.g., Guanidine or
urea) that disrupts hydrogen bonds to inhibit anti-
geneantibody binding.
The avidity index (AI) is based on the understanding
that antibodies show a low avidity in the early phase of
infection, however, with time antibody avidity increases
progressively [6]. The AI has been used in prior studies
of infectious diseases including toxoplasma, rubella, and
cytomegalovirus to diagnose recent primary infections
[7e9]. It is now being applied to other infectious agents
such as hepatitis viruses and herpes viruses [10e12].
Over the past decade, research studies using the AI to
diagnose early HIV infections have been published
[13,14].
Even though several incidence assays have been
developed or are under development [2,15], the Sedia
HIV-1 LAG Avidity EIA (Sedia Biosciences Corp.,
Portland, OR, USA) and the BED assay are commer-
cially available kits [15,16]. Nevertheless, the World
Health Organization Working Group on HIV Incidence
Assays recommends using the BED assay in combina-
tion with another assay measuring different biological
endpoints, such as avidity assay, to compensate for the
limitations of the BED assay, the most important of
which is the generation of false positive results [17].
In setting up the avidity assay, each laboratory has to
resolve various matters such as determining the chaot-
ropic agent and the cutoff value under the optimal con-
dition using reasonable samples such as representative
samples for their regions. In this study, we developed and
optimized an avidity assay using samples from Korean
HIV seroconverters and HIV-positive individuals.2. Materials and methods
2.1. Specimens
We used samples from Korean HIV seroconverters,
HIV-positive Koreans, and two commercial HIV sero-
conversion panels, an HIV-1 incidence performance
panel.
A total of 81 Korean HIV seroconverters were
collected from a pool of HIV seroconverters detected
from 2005 to 2012 at the Korea Centers for Diseases
Control and Prevention (KCDC). A total of 193 speci-
mens collected from these 81 individuals were used in
this study. At least two observations including one
indeterminate specimen with results by several seroim-
munological patterns were carried out prior to the
diagnosis of HIV infection. According to the Fiebig
classification, the infection stage of each person was
grouped into six laboratory stages of primary HIV
infection based on the antigeneantibody response
pattern (HIV RNA, ELISA antigen, ELISA antibody,
and Western blot) found in the first sample [18,19]. We
estimated the HIV infection period for all 193 longitu-
dinal samples using the Fiebig classification.
We selected 135 Korean HIV-positive samples, and
classified two groups. The first group consisted of 30
HIV-positive samples shown positive with HIV nucleic
acid amplification, antigen/antibody ELISA, and
Western blot. The samples were taken from blood
donors to obtain enough volumes for repeated tests,
and these individuals had not received antiretroviral
therapy. These samples were used to select the optimal
concentration of the chaotropic agent, and the preci-
sion of the avidity assay. The second group consisted
of 105 samples obtained from long-term infected per-
sons who passed away more than 2 years after the
initial diagnosis of HIV at the KCDC. The samples
were used to set up the optimal cutoff value in the
avidity assay.
The two sets of HIV seroconversion standard panels
(PRB933, PRB965: BBI; SeraCare, Milford, MA, USA)
used in this study consisted of samples that converted
from negative, to indeterminate, and to positive for HIV
testing; which are the early stage of incidence samples
under 30 days since seroconversion. The standard panel
for HIV-1 incidence performance (PRB601: SeraCare)
contained a total of 15 samples; seven are recent
infection and eight are established infection.
2.2. Laboratory testing: BED assay
The BED assay (Calypte Biomedical Corporation,
Portland, OR, USA) was conducted according to the
manufacturer’s instructions. Samples were diluted to a
ratio of 1:100, transferred to a plate coated with goat-
antihuman-IgG, and incubated for 1 hour at 37C. After
washing, a BED-biotin peptide (gp41) was added after
being diluted at 1:1000. Then, after an additional 1-hour
186 J.-S. Wang, et alincubation at 37C and a second round of washing, a
conjugate, which was diluted 1:1000, was added. This
was followed by a 90-minute incubation at 37C, a third
round of washing, and the addition of 3,30,5,50-Tetra-
methylbenzidine. The samples were then incubated for
15 minutes at 25C and processed using a stop solution.
Finally, using a spectrophotometer, absorbance was
measured at a wavelength of 450 nm.
2.3. Laboratory testing: avidity assay
In the present study, we chose to perform the
AxSYM HIV antigeneantibody Combo assay (Abbott
Laboratories, Wiesbaden, Germany), which is a fourth-
generation assay, to calculate the AI. The chaotropic
agent used in this study was guanidine hydrochloride
(Guanidine: Sigma # G 7294-100ML; Sigma, St. Louis,
MO, USA). Guanidine concentrations used were 1.0M,
1.5M, and 2.0M and for the control, a phosphate-
buffered saline (PBS) solution (PBL06-500ML; Cais-
son Labs, North Logan, UT, USA) was used. Each
sample was divided into 20-ml aliquots, which were
diluted 1:10 with 1.0M, 1.5M, and 2.0M Guanidine or
PBS, left at room temperature for 15 minutes, and then
subjected to the automated AxSYM assay. Based on the
signal/cutoff (S/CO) ratios of the Guanidine and PBS
aliquots, the AI of HIV antibodies was calculated using
the following formula: AI Z (S/CO of the Guanidine
aliquot)/(S/CO of the PBS aliquot).Figure 1. Distribution of the avidity index for the three hum
lineZ avidity cutoff (0.8). EarlyZ the early stage of incidence sam
in the early stage of incidence belong to PRB933 and PRB965 seroc
regarded as zero avidity index in this plot, which had very low titers
30 days and 200 days since seroconversion; Est Z established sam2.4. Statistical analysis
For this study, sensitivity was defined as the pro-
portion to be identified as recent results among the
incident samples in the panels, whereas specificity was
defined as the proportion of samples identified as
established infection among the established samples in
the panels. We also defined that false-reactive was the
misclassified results as established infection among the
recent infection samples, whereas the nonreactive was
the misclassified results as recent infection among the
established infection samples.
To construct a gray zone, we applied the formulad
{cutoff value  [coefficient of variation (CV)  cutoff
value]}dof Suligoi et al [20]. The precision of the
repeat test results was expressed as the CV. The AI
distributions of three sample groupsdearly stage of
incidence, incidence, and establisheddwere compared
using a nonparametric method (Figure 1).
2.5. Ethics statement
Our research protocol was reviewed and approved by
the KCDC Institutional Review Board Ethics Commit-
tee (Approval Number: 2011-03CON-01-R and 2012-
05CON-11-P). All HIV-positive and seroconverter
specimens used in this study are taken from stored
diagnostic materials from HIV diagnoses at the KCDC.
Because all specimens are identified by their serial
number, they do not contain any personally identifiablean immunodeficiency virus (HIV)-positive groups. Dotted
ples (nZ 9) under 30 days since seroconversion; nine samples
onversion panels. Among them, negative incidence results were
of HIV antibodies. IncZ incidence samples (nZ 21) between
ples (n Z 24) more than 200 days since seroconversion.
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the requirement of informed consent, which was
affirmed by the KCDC Institutional Review Board.T
a
b
le
1
.
S
en
si
ti
v
it
y
an
d
sp
ec
ifi
ci
ty
fo
r
re
ce
n
t
in
fe
ct
io
n
b
y
th
e
co
n
ce
n
tr
at
io
n
o
f
G
u
an
id
in
e
an
d
cu
to
ff
in
av
id
it
y
as
sa
y
.
C
u
to
ff
v
al
u
e
C
o
n
ce
n
tr
at
io
n
o
f
G
u
an
id
in
e
1
.0
M
1
.5
M
2
.0
M
N
o
.
o
f
R
(n
Z
7
0
)
S
en
si
ti
v
it
y
(%
)
N
o
.
o
f
E
(n
Z
8
0
)
S
p
ec
ifi
ci
ty
(%
)
N
o
.
o
f
R
(n
Z
7
0
)
S
en
si
ti
v
it
y
(%
)
N
o
.
o
f
E
(n
Z
8
0
)
S
p
ec
ifi
ci
ty
(%
)
N
o
.
o
f
R
(n
Z
7
0
)
S
en
si
ti
v
it
y
(%
)
N
o
.
o
f
E
(n
Z
8
0
)
S
p
0
.7
0
2
0
2
8
.6
7
5
9
3
.8
3
7
5
2
.9
7
5
9
3
.8
4
2
6
0
.0
7
3
0
.7
5
2
3
3
2
.9
7
5
9
3
.8
4
0
5
7
.1
7
5
9
3
.8
4
9
7
0
.0
6
4
0
.8
0
3
1
4
4
.3
7
5
9
3
.8
4
4
6
2
.9
7
5
9
3
.8
5
6
8
0
.0
5
6
0
.8
5
4
0
5
7
.1
7
5
9
3
.8
4
8
6
8
.6
7
1
8
8
.8
5
9
8
4
.3
4
5
0
.9
0
4
2
6
0
.0
7
1
8
8
.8
5
5
7
8
.6
6
3
7
8
.8
6
4
9
1
.4
4
5
0
.9
5
5
0
7
1
.4
5
9
7
3
.8
6
0
8
5
.7
4
2
5
2
.5
6
9
9
8
.6
1
9
1
.0
0
6
1
8
7
.1
4
5
5
6
.3
6
7
9
5
.7
2
4
3
0
.0
7
0
1
0
0
.0
1
2
B
as
ed
o
n
th
e
B
E
D
as
sa
y
re
su
lt
s,
3
0
K
o
re
an
H
IV
-p
o
si
ti
v
e
sa
m
p
le
s
w
er
e
cl
as
si
fi
ed
:
1
4
w
er
e
re
ce
n
t
in
fe
ct
io
n
s
an
d
th
e
o
th
er
1
6
w
er
e
es
ta
b
li
sh
ed
in
fe
ct
io
n
s.
T
h
es
e
H
IV
-i
n
fe
ct
ed
K
o
re
an
s
te
st
ed
p
o
si
ti
v
e
in
t
te
st
sd
n
u
cl
ei
c
ac
id
am
p
li
fi
ca
ti
o
n
,
H
IV
an
ti
g
en
/a
n
ti
b
o
d
y
E
L
IS
A
,
an
d
W
es
te
rn
b
lo
td
an
d
h
ad
n
o
t
re
ce
iv
ed
an
ti
re
tr
o
v
ir
al
th
er
ap
y
.
F
o
r
th
e
av
id
it
y
as
sa
y
,
1
.0
M
,
1
.5
M
,
an
d
2
.0
M
G
u
an
id
in
e
co
n
ce
n
tr
at
io
n
s
w
er
e
u
se
d
,
a
H
IV
p
o
si
ti
v
e
sa
m
p
le
s
w
er
e
te
st
ed
re
p
ea
te
d
ly
u
si
n
g
th
e
as
sa
y
fi
v
e
ti
m
es
(n
Z
1
5
0
).
E
Z
es
ta
b
li
sh
ed
in
fe
ct
io
n
;
E
L
IS
A
Z
en
zy
m
e-
li
n
k
ed
im
m
u
n
o
so
rb
en
t
as
sa
y
;
H
IV
Z
h
u
m
an
im
m
u
n
o
d
efi
ci
en
cy
v
ir
u
s;
R
Z
re
ce
n
t3. Results
3.1. Determination of the concentration of
chaotropic agent for the avidity assay using
HIV-positive samples
The results of the BED assay for the commercial HIV
panels (PRB933, PRB965, and PRB601) were all in
good agreement with the reference results. For each of
the 30 Korean HIV-positive samples, two repeat tests of
the BED assay were performed. The results demon-
strated that 14 were recent infections and the other 16
were long-term infections. The repeat tests gave the
same results (data not shown).
To select an appropriate concentration for the cha-
otropic agent, five repeat tests were performed with
Guanidine concentrations of 1.0M, 1.5M, and 2.0M
each. Based on the BED assay results, the samples were
classified as recent or established infections. We then
calculated the sensitivity and specificity of each Gua-
nidine concentration used in the avidity assay. For
Guanidine concentrations of 1.0M, 1.5M, and 2.0M,
sensitivity and specificity were calculated for the cutoff
value of 0.05 increments from 0.70 to 1.00. Using 1.0M
Guanidine, sensitivity ranged from 28.6% to 87.1%,
which was lower than what was observed using 1.5M or
2.0M Guanidine. However, specificity was highest with
1.0M Guanidine, ranging from 56.3% to 93.8%. By
contrast, sensitivity was highest with 2.0M Guanidine
(60.0e100%), whereas specificity was lowest with 2.0M
Guanidine (15.0e91.3%). We decided that 1.5M Gua-
nidine was the most suitable concentration to use in
consideration of the sensitivity and specificity levels
obtained at most of the cutoff values (Table 1).
3.2. Determination of cutoff value for the
avidity assay using HIV seroconverter
samples
To determine the cutoff value for the avidity assay,
we used samples collected from 81 Korean sero-
converters whose date of HIV infection could be reliably
estimated. The characteristics of these seroconverters
and their longitudinal samples are shown in Table 2.
Regarding the infection period, 40.7% and 46.9% of the
participants fell into Fiebig Stages II and IV, respec-
tively. The results of the Fiebig classification in 193
longitudinal samples showed that 90% of the sero-
converter samples were within 200 days of serocon-
version and were thus classified to be in the early stage
of HIV infection.
An analysis of the BED assay results performed on
these Korean HIV seroconversion samples showed that
Table 2. Classification of HIV seroconverters derived
from 2005 to 2012 in Korea (n Z 193).
Categories Number (%)
Cumulative
no. (%)
Fiebig stagesa (81 individuals)
Eclipse phase d d
I 2 (2.5) 2 (2.5)
II 33 (40.7) 35 (43.2)
III 6 (7.4) 41 (50.6)
IV 38 (46.9) 79 (97.5)
V 2 (2.5) 81 (100.0)
VI d 81 (100.0)
Estimated days (d) following HIV transmissionb
(193 samples)
1e30 20 (10.4) 20 (10.4)
31e60 55 (28.5) 75 (38.9)
61e90 33 (17.1) 108 (56.0)
91e120 29 (15.0) 137 (72.0)
121e150 22 (11.4) 159 (82.4)
151e180 10 (5.2) 169 (87.6)
181e200 5 (2.6) 174 (90.2)
>200 19 (9.8) 193 (100.0)
aFiebig stage of each person was classified into six laboratory stages of
primary HIV infection based on the antigeneantibody response patterns
(HIV RNA, ELISA antigen, ELISA antibody, Western blots) found in the
sample [16,17]. Days following HIV transmission of each stage were as
follows: Eclipse phase (10 days), I (17 days), II (22 days), III (25 days),
IV (31 days), V (101 days), and VI (open ended); bEighty-one individuals
were classified according to the Fiebig system of using the first bleeding
date sample, and the estimated HIV infection period for all 193 samples
was derived from longitudinal samples of the individuals.
ELISA Z enzyme-linked immunosorbent assay; HIV Z human im-
munodeficiency virus.
188 J.-S. Wang, et alat the cutoff value of 0.8 stated in the kit insert for the
BED assay, the most useful recency period was 200 days
(data not shown).
The most optimal cutoff value for the avidity assay
was 0.80 in the Korean seroconverter samples and long-
term infection samples, and the sensitivity and speci-
ficity were 90.2% and 83.8%, respectively, at the cutoffTable 3. Results of the avidity assay on the seroconverters and
Cutoff value
Avidit
Recent infection (n Z 174)
Sensitivity (%) False-reactive
0.55 123 (70.7) 51 (29.3)
0.60 132 (75.9) 42 (24.1)
0.65 141 (81.0) 33 (19.0)
0.70 143 (82.2) 31 (17.8)
0.75 150 (86.2) 24 (13.8)
0.80 157 (90.2) 17 (9.8)
0.85 158 (90.8) 16 (9.2)
0.90 163 (93.7) 11 (6.3)
Recent infection (n Z 174): samples with the seroconversion duration of
Established infection: samples collected from long-term infected persons for mvalue (Table 3). As shown in Table 4, 87.9% (153/174)
of recent infection samples were identified as recent,
whereas 12.3% (13/105) of established infection sam-
ples were all misclassified based on the dual testing
results. The agreement results of the two incidence as-
says were 90.2% (157/174) and 85.7% (90/105) in the
recent infection and established infection samples,
respectively. The BED assay had more false recent re-
sults on the established samples.
3.3. Precision of AI for detecting recent HIV
infections
To ensure the validity of the procedure, we conducted
repeat tests and analyzed the assay’s reproducibility.
Table 5 presents the precision of the AI for five repeat
tests performed on 30 HIV-positive samples treated with
1.5M Guanidine. The mean CV obtained from the five
repeat tests for each of the 30 samples was 5.43%. In
addition, the mean correlation coefficient between the
optical density/CO ratio of AxSYM HIV Antigen/
Antibody and AI was 0.706 (p < 0.001), suggesting a
positive correlation.
Moreover, we established a gray zone to reduce the
error in the identification of recent infections among
samples that showed values close to the cutoff value.
After applying the CV obtained from five repeat tests on
30 HIV-positive samples, we obtained a gray zone of
0.75e0.85 (data not shown).
3.4. Distributions of AI by progression stages of
HIV infection
We divided the samples in PRB933, PRB965, and
PRB601 and 30 Korean HIV-positive samples into three
groupsdsamples in the early stage of incidence (nZ 9;
3 from PRB933 and 6 from PRB965), incident samples
(nZ 21; 7 from PRB601 and 14 from Korean Positive),
and established samples (n Z 24; 8 from PRB601 and
16 from Korean Positive). Each group of samples was
subjected to a Guanidine-based avidity assay with aestablished infection samples by cutoff values.
y assay (1.5M Guanidine)
Established infection (n Z 105)
(%) Specificity (%) Nonreactive (%)
95 (90.5) 10 (9.5)
94 (89.5) 11 (10.5)
92 (87.6) 13 (12.4)
91 (86.7) 14 (13.3)
89 (84.8) 16 (15.2)
88 (83.8) 17 (16.2)
76 (72.4) 29 (27.6)
65 (61.9) 40 (38.1)
200 days were selected from the 193 Korean seroconverter samples.
ore than 2 years after initial diagnosis of human immunodeficiency virus.
Table 4. Results of the two incidence assays on the seroconverters and established infection samples at 0.8 cutoff value.
Test results
Recent infection
(n Z 174)
Established infection
(n Z 105)
BED(Incidence), Avidity(Incidence) 153 (87.9%) 13 (12.3%)
BED(Incidence), Avidity(Established) 11 (6.3%) 11 (10.5%)
BED(Established), Avidity(Incidence) 6 (3.4%) 4 (3.8%)
BED(Established), Avidity(Established) 4 (2.3%) 77 (73.3%)
HIV avidity assay to identify recent HIV infections 189concentration of 1.5M Guanidine to study the distribu-
tion of AI compared with elapsed time since serocon-
version (Figure 1). The median values showed
significant variations between the groups: 0.159, 0.694,
and 0.958 in the early-stage, incident, and established
samples, respectively (p < 0.001).Table 5. Precision of the avidity assay performed on 30
Korean positive samples assessed in five repeat
tests.
No.
Axsym HIV Ag/
Ab (OD/CO)
Avidity index
(mean  SD) CV (%)
1 16.59 0.69  0.03 5.03
2 53.63 1.11  0.10 9.28
3 48.19 0.98  0.04 4.58
4 36.87 1.00  0.07 7.10
5 26.33 0.92  0.04 4.12
6 9.71 0.19  0.01 4.55
7 48.40 0.97  0.08 8.23
8 35.11 0.89  0.05 5.67
9 24.32 0.82  0.03 4.13
10 18.22 0.68  0.05 7.66
11 24.45 0.85  0.05 5.84
12 46.05 0.93  0.04 4.62
13 20.45 0.50  0.03 5.25
14 48.76 1.06  0.03 3.16
15 31.31 0.93  0.03 3.34
16 15.83 0.28  0.02 7.72
17 19.75 0.98  0.03 2.92
18 18.08 0.65  0.04 5.93
19 18.05 0.48  0.04 8.80
20 28.35 1.13  0.04 3.86
21 32.66 0.91  0.05 5.55
22 40.01 0.97  0.04 4.28
23 17.91 0.59  0.04 6.21
24 17.71 0.96  0.05 5.00
25 33.34 0.90  0.04 4.34
26 24.92 0.41  0.03 8.24
27 25.91 0.89  0.04 4.81
28 48.64 1.00  0.03 2.63
29 31.35 0.95  0.02 2.35
30 38.51 0.90  0.07 7.61
The correlation coefficient of between S/Co of AxSYM HIV Ag/Ab
and mean of avidity index is 0.706 (p < 0.001). CV Z coefficient of
variation; HIV Z human immunodeficiency virus; OD/CO Z ratio of
optical density to cutoff value; S/CO Z signal/cutoff; SD Z standard
deviation.3.5. Avidity results on three HIV commercial
incidence panels
The results of the avidity assay on the two sets of
HIV seroconversion panels (PRB933, PRB965) were all
in good agreement with the reference results. In the
performance panel (PRB601), the results showed that
six were recent infections and nine were established
infections. One misclassified sample resulted in false-
reactive with 0.83 AI, which belongs to the gray zone
range (data not shown).4. Discussion
This study showed that for the identification of
recently acquired infections, we could measure HIV
incidence by establishing a laboratory-based serological
test method based on the changes in antigeneantibody
response pattern relative to time since HIV infection.
Even though earlier studies suggested the use of Gua-
nidine or urea as the preferred chaotropic agent for the
avidity assay [21], we found that, from an examination
of panels that contained both incident and established
samples, sensitivity and specificity were highest when
Guanidine was used (data not shown).
The most optimal concentration of Guanidine was
1.5M, and the most useful cutoff for the avidity assay to
detect recent HIV infection was 0.80.
The mean CV obtained from the precision test was
5.43%, which indicated that the entire procedure was
highly precise. In general, precision is defined as the
variability in the results from replicated performance of
the homogeneous sample under the normal assay con-
dition. For enzyme assays, precision is usually <10%
[22].
In this study, at the cutoff value of 0.8 for the BED
assay, samples from HIV seroconverters showed a
recency period of 200 days, which is longer than the
period (155 days) suggested by the kit insert for the
BED assay. However, recent studies have also reported
similar findings. According to Braunstein et al [23],
prospective seroconverters among Rwandan sex workers
showed a mean recency period of 330 days. In addition,
a study conducted by Parekh et al [24] on longitudinal
specimens collected from various groups showed a
recency period of 197 days. As a result, the U.S. Centers
190 J.-S. Wang, et alfor Disease Control and Prevention were planning to
adjust the recency period stated in the BED kit insert in
consideration of the findings cited above.
Generally, when trying to establish an avidity assay,
various obstacles must be overcome. First, each labo-
ratory has to validate the methods used for the entire
procedure including selection of an appropriate chaot-
ropic agent for the AI and determination of the cutoff
value. Second, it is difficult to secure panels that reflect
a diverse period of infection stages and for which the
date of seroconversion can be estimated. Third, there
may be limitations to interpreting HIV incidence test
results because they are determined solely by the AI.
Not only are there individual differences in the immune
response to HIV, window periods also vary by HIV
subtype or race [24]. In this study, 9.8% of recent
infection samples and 16.2% of established infection
samples were misclassified in the avidity assay (Table
3). Furthermore, 2.3% (4/174) of recent infection sam-
ples were all misclassified as established infection from
the two incidence assays (Table 4). These discordant
results of studies have been reported by Braunstein et al
[23] and Moyo et al [25]. Therefore, incidence assay
results should be analyzed in combination with other
information such as HIV test results and patient’s his-
tory [26].
Despite these limitations, this study is important
because it enabled the establishment of an avidity assay
using Korean samples from HIV-positive and sero-
converters. It will enhance the reliability of the estimation
of HIV incidence by combining data from both the avidity
assay and the BED assay and comparing the results. In
addition, a gray zone was included so that samples with
values close to the cutoff point, and thus difficult to
determine, would be subjected to further testing. In this
case, we interpreted the results comprehensive-
lydconsidering laboratory examination data such as
antigen test results, nucleic acid analysis, CD4þ T cell
count, and patient information such as treatment history.
This led to a more accurate discrimination between recent
and established infections and reduced the risk of
misclassification. It seems, however, that further research
will need to be conducted using samples that showed
conflicting results in the BED and avidity assays from an
immunological and serological perspective. We expect
that a comprehensive algorithm to analyze incidence
assay results will emerge from such future research.
The incidence assay established in this study is very
significant because it enables the detection of recent
infections among newly reported cases of HIV using a
serological test method. Furthermore, the results provide
basic data to assess HIV incidence, the progression of
the disease after infection, and the survival rate. This is
the first study on recent HIV infection assays, and it will
help in epidemiologic studies of HIV/AIDS and can be
applied to the national HIV/AIDS prevention policy in
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